Abstract | OBJECTIVES: To evaluate the efficacy and tolerability of losigamone (LSG). PATIENTS AND METHODS: Double-blind, placebo-controlled add-on study with 3x500 mg LSG/die for the treatment of chronic partial seizures in 203 patients (99 treated with LSG, 104 on placebo). RESULTS: The median percent change of seizures was 14.9% (LSG) versus 6.7% (placebo) (P=0.004). Seizure frequency was decreased by more than 50% in 22.3% (LSG) and 14.6% (placebo) of patients (P=0.13). Mean percent change of seizures was best in patients with only one additional anticonvulsant drug (LSG versus placebo, P=0.004). Adverse events (usually CNS-related side effects of mild to moderate intensity) were reported in 59.6% (LSG) and 37.5% (placebo) of patients. CONCLUSIONS:
|
Authors | J Bauer, A Dienel, C E Elger, Losigamone Study Group |
Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 103
Issue 4
Pg. 226-30
(Apr 2001)
ISSN: 0001-6314 [Print] Denmark |
PMID | 11328193
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anticonvulsants
- Furans
- losigame
|
Topics |
- Adolescent
- Adult
- Anticonvulsants
(therapeutic use)
- Double-Blind Method
- Drug Therapy, Combination
- Epilepsies, Partial
(drug therapy)
- Female
- Furans
(therapeutic use)
- Humans
- Male
- Middle Aged
- Treatment Outcome
|